 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Medarex, Inc.
 |
Medarex, Inc. |
 |
 |
 |
PROFILE |
 |
Rather than building a better mousetrap, Medarex is building a better mouse. The company uses genetically engineered mice (called HuMAb-Mice) to create human monoclonal antibodies and develop therapeutic products. It has more than 30 development partnerships with pharmaceutical and biotechnology firms that target cancer and transplant rejection, as well as cardiovascular, autoimmune, inflammatory, and other diseases. These partners include Aventis Behring, with which it is developing MDX-33, a potential autoimmune blood disorder treatment; Novo Nordisk; and Oxford GlycoSciences. Medarex owns more than 30% of Genmab, a Danish concern that uses the company's HuMAb-Mice technology to develop drug candidates.
COMPETITION |
 |
Abgenix, Inc. (ABGX)
Genentech, Inc. (DNA)
Protein Design Labs, Inc. (PDLI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 22.50
1-Yr. Sales Growth: 127.3%
Employees: 136
Revenue per employee: $165,441.18
KEY PEOPLE |
 |
Donald L. Drakeman
CEO
Christian S. Schade
CFO
CONTACT INFO |
 |
707 State Rd., Ste. 206
Princeton, NJ 08540
US
Phone: 609-430-2880
Fax: 609-430-2850
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |